What is the physiological, safety, efficacy and compliance-focused rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation? How does this impact FPG and PPG control?

What is the physiological, safety, efficacy and compliance-focused rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation? How does this impact FPG and PPG control?

What is the physiological, safety, efficacy and compliance-focused rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation? And how does this strategy impact pan-glycemic—FPG and PPG—control?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Serge Jabbour, MD, FACP, FACE

Serge Jabbour, MD, FACP, FACE

Professor of Medicine Thomas Jefferson University Division of Endocrinology, Diabetes and Metabolic Diseases Department of Medicine Jefferson Medical College Philadelphia, Pennsylvania